FDA Clocks In Patent Extension Time for SKYCLARYS Drug
Published Date: 5/12/2025
Notice
Summary
The FDA has officially set the review period for SKYCLARYS, a new medicine, so its patent can be extended. This means the company behind SKYCLARYS gets more time to protect their invention before others can copy it. If you’re in the drug business or follow patents, this update affects when the patent extension starts and could impact market timing and profits.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Sets Review Period for SKYCLARYS
The Food and Drug Administration (FDA) determined the regulatory review period for the drug SKYCLARYS and published a notice of that determination. That determination is tied to an application to the U.S. Patent and Trademark Office (USPTO) to extend a patent that claims this human drug product, which can give the patent holder more time to keep competitors from marketing the same drug.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in